Background/Aims: Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for use in heparin-induced thrombocytopenia (HIT; several countries) and in antithrombin-deficient patients undergoing hemodialysis (Japan). This literature analysis aimed to determine the effects of renal function on argatroban pharmacokinetics, pharmacodynamics, and its therapeutic dose in HIT and to evaluate argatroban dosing and safety during renal replacement therapy (RRT) and in adults with renal dysfunction undergoing surgical or invasive procedures. Methods: A literature search identified 34 publications (12 prospective studies, 4 retrospective studies, 18 anecdotal reports) that together described 644 argatroban-treated patients (446 with HIT, 82 with antithrombin deficiency) with varying degrees of renal function. Pertinent data were extracted and summarized. Results: In pharmacokinetic studies (40 patients, overall), renal dysfunction exerted little or no clinically significant effects on argatroban pharmacokinetic parameters. For argatroban therapy in HIT, evidence existed that an initial 2 µg/kg/min dose was sometimes excessive; patients with hepatic dysfunction, irrespective of renal function, required reduced initial doses; lesser doses were required in combined hepatic and renal dysfunction than hepatic dysfunction, and for each 30 ml/min decrease in patient creatinine clearance, the therapeutic dose decreased ∼0.1–0.6 µg/kg/min. Argatroban was well tolerated and enabled RRT with little or no thrombotic or hemorrhagic complications. Experiences with argatroban in renally impaired patients undergoing procedures besides RRT were limited. Conclusion: Current literature suggests that argatroban is well tolerated and provides adequate anticoagulation in patients with renal dysfunction or failure, including individuals with HIT or antithrombin deficiency where anticoagulant options are limited.

Keywords:
Argatroban, Renal dysfunction, Renal replacement therapy, Dialysis, Heparin-induced thrombocytopenia, Antithrombin deficiency
1.
Hara T, Naito K: Inherited antithrombin deficiency and end stage renal disease. Med Sci Monit 2005;11:RA346–RA354.
2.
Martel N, Lee J, Wells PS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106:2710–2715.
3.
Hirsh J, Heddle N, Kelton JG: Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004;164:361–369.
4.
Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004;126:311S–337S.
5.
Swan SK, Hursting MJ: The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318–329.
6.
Argatroban Injection Prescribing Information: GlaxoSmithKline, Research Triangle Park, July 2005.
7.
Izawa O, Katsuki M, Komatsu T, Iida S: Pharmacokinetics studies of argatroban (MD805) in human – concentrations of argatroban and its metabolites in plasma, urine, and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 1986;14(suppl 5):251–263.
8.
Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang I-K, Rifkin SD, Moran J, Hursting MJ, Kelton JG: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838–1843.
9.
Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Int Med 2003;163:1849–1856.
10.
Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T: Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996;28:82–85.
11.
Murray PT, Hursting MJ: Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Renal Failure 2006;28:537–539.
12.
Hartman V, Malbrain M, Daelemans R, Meersman P, Zachee P: Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 2006;104:c143–c148.
13.
Fischer K-G: Hirudin in renal insufficiency. Semin Thromb Hemost 2002;28:467–482.
14.
O’Shea SI, Ortel TL, Kovalik EC: Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003;16:61–67.
15.
McIntosh BA: Developing an algorithm for treating heparin-induced thrombocytopenia. Clin Adv Hematol Oncol 2002;2:216–222.
16.
Matsuo T, Yamada T, Yamanashi Y, Kodama K: Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis. Clin Lab Haematol 1989;11:213–219.
17.
Matsuo T, Yamada T, Matsuo M, Sakai R: Anticoagulant therapy in a congenital antithrombin III (ATIII)-deficient patient with chronic renal failure undergoing regular hemodialysis. Biomater Artif Cells Immobilization Biotechnol 1991;19:185–191.
18.
Kubiak DW, Szumita PM, Fanikos JR: Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1119–1123.
19.
Spinler SA, Dager W: Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1955–1956.
20.
Mejak B, Giacomuzzi C, Hefler E, You X, Underleider R, Shen I, Boshkov L: Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 2004;36:178–181.
21.
Hursting MJ, Dubb J, Verme-Gibboney CN: Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol 2006;28:4–10.
22.
Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005;39:1601–1605.
23.
Ota K, Kawaguchi H, Nakagawa S, Koshikawa S, Maeda K, Matsui N, Hirasawa Y, Sasaoka T: Clinical evaluation of a new thrombin inhibitor available for haemodialysis. Proc Eur Dial Transplant Assoc 1983;20:144–149.
24.
Matsuo T, Nakao K, Yamada T, Matsuo O: Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit. Thromb Res 1986;41:33–41.
25.
Matsuo T, Chikahira Y, Yamada T, Nakao K, Ueshima S, Matsuo O: Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1988;52:165–171.
26.
Kario K, Matsuo T, Yamada T, Matsuo M: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994;71:275–279.
27.
Ohteki H, Furukawa K, Ohnishi H, Narita Y, Sakai M, Doi K: Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 2000;48:39–46.
28.
Akashi K, Masui Y, Soma K, Kawada T, Takahoshi Y, Yamanaka I, Inokuchi S, Sugiyama M: Clinical trial of argatroban, a direct thrombin inhibitor, as an anticoagulant in cardiopulmonary support and apheresis in emergency patients: a preliminary report. J Artif Organs 2002;5:223–227.
29.
Arpino PA, Hallisey RK: Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004;38:25–29.
30.
Murray PM, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, Tang I, Hursting MJ, Shamp TR, Swan SK: A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004;66:2446–2453.
31.
Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT: Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005;39:231–236.
32.
Koster A, Hentschel T, Groman T, Kuppe H, Hetzer R, Harder S, Fischer K-G: Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 2007;133:1376–1377.
33.
Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N: Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003;18:1623–1630.
34.
Guzzi LM, McCollum DA, Hursting MJ: Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006;22:169–176.
35.
Levine RL, Hursting MJ, McCollum D: Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006;129:1167–1175.
36.
Matsuo T, Nakao K, Yamada T, Matsuo O: A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis. Thromb Res 1986;44:247–251.
37.
Matsuo T, Yamada T, Yamanashi T, Ryo R: Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia. Thromb Res 1990;58:663–666.
38.
Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T: Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992;82:627–629.
39.
Koide M, Yamamato S, Matsuo M, Suzuki S, Arima N, Matsuo T: Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995;10:2137–2140.
40.
Lewis BE, Grassman ED, Wrona L, Rangel Y: Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:54–58.
41.
Dager WE, White RH: Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Ann Pharmacother 2003;37:1232–1236.
42.
De Denus S, Spinler SA: Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 2003;37:1237–1240.
43.
Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY: Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652–654.
44.
Tokuda Y, Matsumoto M, Sugita T, Nishizawa J, Matsuyama K, Yoshida K, Matsuo T: Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia. Circ J 2003;67:889–890.
45.
Edwards JT, Hamby JK, Worrall NK: Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003;75:1622–1624.
46.
Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G: Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24:409–414.
47.
Hara T, Jojima K, Takeuchi K, Takai K, Naito K: Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis. Thromb Haemost 2004;92:208–210.
48.
Hallman SE, Hebbar L, Robison J, Uber WE: The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia. Anesth Analg 2005;100:946–948.
49.
Scott LK, Grier LR, Conrad SA: Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal membrane oxygenation managed with argatroban. Pediatr Crit Care Med 2006;7:473–475.
50.
Zangan SM, Van Ha TG, Funaki B: Systemic anticoagulation with argatroban during arteriovenous dialysis graft thrombolysis. J Vasc Interv Radiol 2006;17:1717–1718.
51.
Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177–184.
52.
Jang IK, Lewis BE, Matthai WH, Kleiman NS: Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label nonrandomized pilot study. J Thromb Thrombolysis 2004;18:31–37.
53.
Dreisbach AW, Lertora JJ: The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003;16:45–50.
54.
Krieger D, Geisen U, Is A, Fischer KG: Hemodialyser membranes allow for removal of argatroban. J Thromb Haemost 2007;5(suppl 1):P-S-669.
55.
Smythe M, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost 2005;11:371–374.
56.
Kiser TH, Jung R, MacLaren R, Fish DN: Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005;25:1736–1745.
57.
Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L: Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006;21:86–92.
58.
Rice L, Hursting MH, Baillie GM, McCollum DA: Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007;47:1028–1034.
59.
Novastan® Injection (Argatroban Preparation) Prescribing Information: Mitsubishi Chemical Corp, Tokyo, March 1998.
60.
Malherbe S, Tsui B, Stobart K, Koller J: Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004;100:443–445.
61.
Alsoufi B, Boshkov LK, Kirby A, Ibsen L, Dower N, Shen I, Underlierder R: Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004;7:155–171.
62.
Yee AJ, Kuter DJ: Successful recovery after an overdose of argatroban. Ann Pharmacother 2006;40:336–339.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.